ATHENS, Ga., Sept. 9 /PRNewswire/ -- ArunA Biomedical, Inc., the first company to commercialize human embryonic stem cell derived products and services, announced today the appointment of former Serologicals Corporation CFO, Harold "Bud" Ingalls, to its Board of Directors.
Mr. Ingalls brings over 40 years of financial leadership, including nearly 20 years of experience as a chief financial officer to ArunA's Board. Prior to his current role as CFO of Premier Exhibitions, Mr. Ingalls served as Vice President and Chief Financial Officer at CardioMEMS, where he played a key role in the organization's transformation. During his tenure at CardioMEMS, Mr. Ingalls led the completion of two private financing rounds totaling over $45 million with venture capitalists and strategic investors. From 2001 to 2006, he held the position of Vice President of Finance and Chief Financial Officer of Serologicals Corporation. Under Mr. Ingalls' leadership, Serologicals' enterprise value increased by nearly $1.0 billion, as the result of strong organic growth, successful acquisitions and stringent cost control. Prior to his work with Serologicals, Mr. Ingalls was employed as President and Chief Financial Officer of LaRoche Industries, Inc. Mr. Ingalls is a member of the American Institute of Certified Public Accountants and received a BBA degree in Accounting from the University of Wisconsin.
"We are pleased to welcome Bud to the ArunA Board. His domain knowledge and impressive combination of strategic and financial expertise in the life sciences industry will be a tremendous asset to ArunA Biomedical as we move forward in our next phase of growth," said ArunA President and CEO, William T. Sharp.
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.
For more information, visit: http://www.arunabiomedical.com
|SOURCE ArunA Biomedical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved